Formula for success as Martyn Greenacre joins board
This article was originally published in Scrip
Executive Summary
Oncology drug development company Formula Pharmaceuticals has appointed Martyn Greenacre to its board of directors. Previously, Mr Greenacre served as chair of BMP Sunstone Corporation before its acquisition by Sanofi-Aventis, CEO and a director of Delsys Pharmaceutical Corporation, and president and CEO of Zynaxis.